Plasma levels of NT-pro-brain natriuretic peptide in patients with overt and subclinical hyperthyroidism and hypothyroidism

Endokrynologia Polska

Volumn 62, Issue 6, 2011, Pages 523-528

  Pakuła, Dorota ^a   Marek, Bogdan ^a,b   Kajdaniuk, Dariusz ^a,b   Krysiak, Robert ^b   Kos Kudła, Beata ^b   Pakuła, Piotr ^a   Gatnar, Aleksander ^a   Borgiel Marek, Halina ^b   Nowak, Mariusz ^b   Siemińska, Lucyna ^b   Głogowska Szela̧g, Joanna ^b   Ostrowska, Zofia ^b  

^a Voivodeship Specialistic Hospital No 3   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

BNP; Brain natriuretic peptide; Hyperthyroidism; Hypothyroidism; L thyroxine; NT pro BNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; LEVOTHYROXINE; THYROID HORMONE;

ARTICLE; AUTOIMMUNE HYPOTHYROIDISM; CONTROLLED STUDY; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; PROTEIN BLOOD LEVEL; THYROID GLAND; TOXIC GOITER;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTHYROIDISM; HYPOTHYROIDISM; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; THYROXINE;

EID: 84555187614     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Gardner DG, Chen S, Glenn DJ et al. Molecular biology of the natriuretic peptide system: implications for physiology and hypertension. Hypertension 2007; 49: 419-426.
2. Maack T. The broad homeostatic role of natriuretic peptides. Arq Bras Endocrinol Metabol 2006; 50: 198-207. (Pubitemid 43799106)
3. Mair J. Biochemistry of B-type natriuretic peptide - where are we now? Clin Chem Lab Med 2008; 46: 1507-1514.
4. Di Angelantonio E, Chowdhury R, Sarwar N et al. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 2009; 120: 2177-1287.
5. Kuwahara K, Nakao K. Regulation and significance of atrial and brain natriuretic peptides as cardiac hormones. Endocr J 2010; 57: 555-565.
6. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339: 321-328. (Pubitemid 28366422)
7. Boerrigter G, Costello-Boerrigter LC, Burnett JC Jr. Natriuretic peptides in the diagnosis and management of chronic heart failure. Heart Fail CUn 2009; 5: 501-514.
8. Palazzuoli A, Gallotta M, Quatrini I, Nuti R. Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure. Vasc Health Risk Manag 2010; 6: 411-118.
9. McKie PM, Burnett JC Jr. B-type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities. Mayo Clin Proc 2005; 80: 1029-1036. (Pubitemid 41099389)
10. Yap LB, Mukerjee D, Timms PM et al. Natriuretic peptides, respiratory disease, and the right heart. Chest 2004; 126: 1330-1336. (Pubitemid 39391268)
11. Christ-Crain M, Morgenthaler NG, Meier C et al. Pro-A-type and N-terminal pro-B-type natriuretic peptides in different thyroid function states. Swiss Med Wkly 2005; 135: 549-554. (Pubitemid 41639942)
12. Ertugrul DT Gursoy A, Sahin M et al. Evaluation of brain natriuretic peptide levels in hyperthyroidism and hypothyroidism. J Natl Med Assoc 2008; 100: 401-405.
13. Kohno M, Horio T, Yasunari K et al. Stimulation of brain natriuretic peptide release from the heart by thyroid hormone. Metabolism 1993; 42: 1059-1064. (Pubitemid 23230441)
14. Ozmen B, Ozmen D, Parildar Z et al. Serum N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) levels in hyperthyroidism and hypothyroidism. Endocr Res 2007; 32: 1-8.
15. Wei T, Zeng C, Tian Y et al. B-type natriuretic peptide in patients with clinical hyperthyroidism. J Endocrinol Invest 2005; 28: 8-11. (Pubitemid 43162802)
16. Kato K, Murakami H, Isozaki O et al. Serum concentrations of BNP and ANP in patients with thyrotoxicosis. Endocr J. 2009; 56: 17-27.
17. Schultz M, Faber J, Kistorp C et al. N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) in different thyroid function states. Clin Endocrinol (Oxf) 2004; 60: 54-59. (Pubitemid 38183498)
18. Schultz M, Kistorp C, Corell P et al. N-terminal-pro-B-type natriuretic peptide during pharmacological heart rate reduction in hyperthyroidism. Horm Metab Res. 2009; 41: 302-307.
19. Nagasaki T, Inaba M, Shirakawa K et al. Increased levels of C-reactive protein in hypothyroid patients and its correlation with arterial stiffness in the common carotid artery. Biomed Pharmacother 2007; 61: 167-172. (Pubitemid 46561189)
20. Weetman AP. Cellular immune responses in autoimmune thyroid disease. Clin Endocrinol (Oxf). 2004; 61: 405-113.
21. Cabral MD, Teixeira Pde F, Leite SP et al. Markers of endothelial function in hypothyroidism. Arq Bras Endocrinol Metabol 2009; 53: 303-309.
22. Sekeroglu MR, Altun ZB, Algün E et al. Serum cytokines and bone metabolism in patients with thyroid dysfunction. Adv Ther 2006; 23: 475-480. (Pubitemid 44409554)
23. Liang F, Webb P, Marimuthu A et al. Triiodothyronine increases brain natriuretic peptide (BNP) gene transcription and amplifies endothelin-dependent BNP gene transcription and hypertrophy in neonatal rat ventricular myocytes. J Biol Chem 2003; 278: 15073-15083. (Pubitemid 36799841)
24. Schultz M, Kistorp C, Langdahl B et al. N-terminal-pro-B-type natriuretic peptide in acute hyperthyroidism. Thyroid 2007; 17: 237-241. (Pubitemid 46557372)
25. Ertugrul DT Yavuz B, Ata N et al. Decreasing brain natriuretic peptide levels after treatment for hyperthyroidism. Endocr J 2009; 56: 1043-1048.